Drug Trial Radar · NCT06830720
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,250
Planned (sponsor's estimate)
Start
Feb 20, 2025
Primary completion
Jun 30, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 17, 2025
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence, as well as patient compliance and quality of life.
Conditions
- Breast Neoplasms
Interventions
ribociclib + AI ± LHRHDrug
ribociclib in combination with an aromatase inhibitor ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
abemaciclib + ET ± LHRHDrug
abemaciclib in combination with an endocrine therapy ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
ET mono ± LHRHDrug
endocrine monotherapy ± LHRH. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive disease-free survival (iDFS) for adjuvant therapy with ribociclib + AI ± LHRH in participants with HR+/HER2- eBC at high risk of recurrenceTime frame: 36 months
Locations
287 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Graz, Austria · Recruiting
Novartis Investigative Site
Klagenfurt, Austria · Recruiting
Novartis Investigative Site
Leoben, Austria · Recruiting
Novartis Investigative Site
Schwaz, Austria · Recruiting
Novartis Investigative Site
Steyr, Austria · Recruiting
Novartis Investigative Site
Vienna, Austria · Recruiting
Novartis Investigative Site
Vienna, Austria · Recruiting
Novartis Investigative Site
Vienna, Austria · Recruiting
Novartis Investigative Site
Vienna, Austria · Recruiting
Novartis Investigative Site
Wiener Neustadt, Lower Austria, Austria · Recruiting
Novartis Investigative Site
Innsbruck, Tyrol, Austria · Recruiting
Novartis Investigative Site
Linz, Upper Austria, Austria · Recruiting
Novartis Investigative Site
Aachen, Germany · Recruiting
Novartis Investigative Site
Amberg, Germany · Recruiting
Novartis Investigative Site
Apolda, Germany · Recruiting
Novartis Investigative Site
Arnsberg, Germany · Recruiting
Novartis Investigative Site
Augsburg, Germany · Recruiting
Novartis Investigative Site
Bad Friedrichshall, Germany · Recruiting
Novartis Investigative Site
Bad Kreuznach, Germany · Recruiting
Novartis Investigative Site
Bad Langensalza, Germany · Recruiting
Novartis Investigative Site
Bad Mergentheim, Germany · Recruiting
Novartis Investigative Site
Bad Reichenhall, Germany · Recruiting
Novartis Investigative Site
Bad Saarow, Germany · Recruiting
Novartis Investigative Site
Bad Soden, Germany · Recruiting
Novartis Investigative Site
Balingen, Germany · Recruiting
Novartis Investigative Site
Bautzen, Germany · Recruiting
Novartis Investigative Site
Bayreuth, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Biberach, Germany · Recruiting
Novartis Investigative Site
Böblingen, Germany · Recruiting
Novartis Investigative Site
Bochum, Germany · Recruiting
Novartis Investigative Site
Bonn, Germany · Recruiting
Novartis Investigative Site
Bonn, Germany · Recruiting
Novartis Investigative Site
Bonn, Germany · Recruiting
Novartis Investigative Site
Bottrop, Germany · Recruiting
Showing 40 of 287 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.